InsiderTrades

Form 4 for TRVI Trevi Therapeutics, Inc.

Accepted 2024-05-22 00:00:00 ET · period of report 2024-05-20 · accession 0000950170-24-063531 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2024-05-22 2024-05-20 TRVI GOOD JENNIFER L Pres, CEO, Dir M - OptEx $2.19 +25.0K 238.3K +12% +$54.8K
D 2024-05-22 2024-05-20 TRVI GOOD JENNIFER L Pres, CEO, Dir S - Sale+OE $2.86 -25.0K 213.3K -11% -$71.6K
D 2024-05-22 2024-05-20 TRVI GOOD JENNIFER L Pres, CEO, Dir M - OptEx $0.00 -25.0K 33.2K -43% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2024-05-20 M A 25,037 $2.19 238,350 D — —
2 Common Common Stock 2024-05-20 S D 25,037 $2.86 213,313 D — — (F1) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.82 to $2.955 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
3 Derivative Stock Option (right to buy) 2024-05-20 M D 25,037 $0.00 33,189 D $2.19 · — to 2024-07-01 25,037 Common Stock (F2) This option was granted on July 2, 2014. The 62,804 shares of common stock underlying the option vested as to 25% of the shares on June 11, 2015 and vested as to the remaining 75% of the shares in equal monthly installments thereafter through June 11, 2018.